COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

ICCVAM Logo

ICCVAM Biennial Report 2018-2019

ICCVAM Biennial Report 2018-2019
Menu
https://ntp.niehs.nih.gov/go/892769

Guidance on Nonclinical Development of Pharmaceuticals for Hematologic Disorders

The FDA guidance document “Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals” was finalized in March of 2019. This guidance is intended to streamline the development of pharmaceuticals used to treat patients with serious noncancer hematologic disorders such as sickle cell disease, hemophilia, and aplastic anemia. The guidance notes scenarios when use of animal studies can be reduced by eliminating or delaying certain nonclinical studies.

"Guidance on Reproductive Toxicity ..." - previous article
next article - "Medical Device Development Tools ..."
Tags: